Bispecific T cell Engager (BiTE®) technology is designed to bind polyclonal cytotoxic T cells and targeted malignant cells1,2,8

Running time: 2:03

The BiTE® antibody construct is engineered from two flexibly linked, single-chain antibodies 2: One antibody is specific for a selected surface antigen on targeted malignant cells2 The other antibody is specific for CD 3—tied to the T-cell receptor complex on the surface of T cells2 BiTE® REPRESENTS AN INNOVATIVE AREA OF RESEARCH IN THE EVOLUTION OF ANTIBODY-BASED IMMUNE THERAPEUTICS WHOSE CLINICAL EFFECTIVENESS IS CURRENTLY BEING INVESTIGATED BY AMGEN.2,8